Forced diuresis with matched hydration in reducing acute kidney injury during transcatheter aortic valve implantation (Reduce-AKI): Study protocol for a randomized sham-controlled trial

Yaron Arbel, Eyal Ben-Assa, Amir Halkin, Gad Keren, Arie L. Schwartz, Ofer Havakuk, Eran Leshem-Rubinow, Maayan Konigstein, Arie Steinvil, Yigal Abramowitz, Ariel Finkelstein, Shmuel Banai

Research output: Contribution to journalArticlepeer-review

14 Scopus citations

Abstract

Background: Acute kidney injury (AKI) is observed in up to 41% of patients undergoing transcatheter aortic valve implantation (TAVI) and is associated with increased risk for mortality. The aim of the present study is to evaluate whether furosemide-induced diuresis with matched isotonic intravenous hydration using the RenalGuard system reduces AKI in patients undergoing TAVI.Methods/Design: Reduce-AKI is a randomized sham-controlled study designed to examine the effect of an automated matched hydration system in the prevention of AKI in patients undergoing TAVI. Patients will be randomized in a 1:1 fashion to the RenalGuard system (active group) versus non-matched saline infusion (sham-controlled group). Both arms receive standard overnight saline infusion and N-acetyl cysteine before the procedure.Discussion: The Reduce-AKI trial will investigate whether the use of automated forced diuresis with matched saline infusion is an effective therapeutic tool to reduce the occurrence of AKI in patients undergoing TAVI.Trial registration: Clinicaltrials.gov: NCT01866800, 30 April 30 2013.

Original languageEnglish
Article number262
JournalTrials
Volume15
Issue number1
DOIs
StatePublished - 2 Jul 2014
Externally publishedYes

Fingerprint

Dive into the research topics of 'Forced diuresis with matched hydration in reducing acute kidney injury during transcatheter aortic valve implantation (Reduce-AKI): Study protocol for a randomized sham-controlled trial'. Together they form a unique fingerprint.

Cite this